Variants in the CNR1 and the FAAH genes and adiposity traits in the community

Obesity

Volumn 17, Issue 4, 2009, Pages 755-760

  Lieb, Wolfgang ^a   Manning, Alisa K ^b   Florez, Jose C ^c,d   Dupuis, Josée ^b   Cupples, L Adrienne ^b   McAteer, Jarred B ^c,e   Vasan, Ramachandran S ^a   Hoffmann, Udo ^c   O'Donnell, Christopher J ^a   Meigs, James B ^c   Fox, Caroline S ^a,f  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; CANNABINOID RECEPTOR; FATTY ACID AMIDASE; FATTY-ACID AMIDE HYDROLASE;

AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HUMAN; INTRAABDOMINAL FAT; MALE; MIDDLE AGED; OBESITY; SINGLE NUCLEOTIDE POLYMORPHISM; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE;

ADIPOSITY; AGED; AMIDOHYDROLASES; BODY MASS INDEX; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CANNABINOID; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE;

EID: 63049107495     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.608     Document Type: Article

References (37)

1. Parikh NI, Pencina MJ, Wang TJ et al. Increasing trends in incidence of overweight and obesity over 5 decades. Am J Med 2007;120:242-250.
2. York DA, Rossner S, Caterson I et al. Prevention Conference VII: obesity, a worldwide epidemic related to heart disease and stroke: Group I: worldwide demographics of obesity. Circulation 2004;110:e463-e470.
3. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555.
4. Atwood LD, Heard-Costa NL, Cupples LA et al. Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study. Am J Hum Genet 2002;71:1044-1050.
5. Estourgie-van Burk GF, Bartels M, van Beijsterveldt TC, Delemarre-van de Waal HA, Boomsma DI. Body size in five-year-old twins: heritability and comparison to singleton standards. Twin Res Hum Genet 2006;9: 646-655.
6. Fox CS, Heard-Costa NL, Wilson PW et al. Genome-wide linkage to chromosome 6 for waist circumference in the Framingham Heart Study. Diabetes 2004;53:1399-1402.
7. Fox CS, Heard-Costa NL, Vasan RS et al. Genomewide linkage analysis of weight change in the Framingham Heart Study. J Clin Endocrinol Metab 2005;90:3197-3201.
8. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116:39-48.
9. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007;18:27-37.
10. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8:585-589.
11. Ravinet-Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004;28:640-648.
12. Poirier B, Bidouard JP, Cadrouvele C et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005;7:65-72.
13. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134.
14. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397.
15. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-1672.
16. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-775.
17. Gary-Bobo M, Elachouri G, Gallas JF et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007;46:122-129.
18. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003;4:873-884.
19. Howlett AC, Barth F, Bonner TI et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54: 161-202.
20. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999;143:315-317.
21. Wiley JL, Burston JJ, Leggett DC et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005;145:293-300.
22. Chambers AP, Sharkey KA, Koopmans HS. Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. Physiol Behav 2004;82:863-869.
23. Colombo G, Agabio R, Diaz G et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998;63:L113-L117.
24. Cravatt BF, Giang DK, Mayfield SP et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-87.
25. Engeli S, Bohnke J, Feldpausch M et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-2843.
26. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979;110:281-290.
27. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
28. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998;62:1198-1211.
29. Benzinou M, Chèvre JC, Ward KJ et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Hum Mol Genet 2008;17:1916-1921.
30. Russo P, Strazzullo P, Cappuccio FP et al. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab 2007;92:2382-2386.
31. Gazzerro P, Caruso MG, Notarnicola M et al. Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes (Lond) 2007;31:908-912.
32. Peeters A, Beckers S, Mertens I, Van Hul W, Van Gaal L. The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine 2007;31:138-141.
33. Müller TD, Reichwald K, Wermter AK et al. No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. Mol Genet Metab 2007;90:429-434.
34. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond) 2005;29:755-759.
35. Jensen DP, Andreasen CH, Andersen MK et al. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites. J Mol Med 2007;85:445-449.
36. Maurovich-Horvat P, Massaro J, Fox CS et al. Comparison of anthropometric, area- and volume-based assessment of abdominal subcutaneous and visceral adipose tissue volumes using multi-detector computed tomography. Int J Obes (Lond) 2007;31:500-506.
37. National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Anthropometry Procedures Manual. National Center for Health Statistics (NCHS). 2008.